Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $13.9 million.

  • Compass Therapeutics' Change in Acquisitions & Divestments fell 5952.22% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.4 million, marking a year-over-year decrease of 3644.85%. This contributed to the annual value of $135.0 million for FY2024, which is 2600.64% down from last year.
  • Per Compass Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $13.9 million for Q3 2025, which was down 5952.22% from $26.8 million recorded in Q2 2025.
  • Compass Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $59.2 million during Q1 2023, with a 5-year trough of $13.9 million in Q3 2025.
  • Its 3-year average for Change in Acquisitions & Divestments is $35.9 million, with a median of $36.4 million in 2025.
  • In the last 5 years, Compass Therapeutics' Change in Acquisitions & Divestments surged by 44.4% in 2024 and then tumbled by 5952.22% in 2025.
  • Quarter analysis of 3 years shows Compass Therapeutics' Change in Acquisitions & Divestments stood at $51.4 million in 2023, then crashed by 50.91% to $25.2 million in 2024, then plummeted by 44.8% to $13.9 million in 2025.
  • Its last three reported values are $13.9 million in Q3 2025, $26.8 million for Q2 2025, and $36.4 million during Q1 2025.